Transgenic pigs expressing human CD59 and decay-accelerating factor produce an intrinsic barrier to complement-mediated damage

Transplantation

Volumn 63, Issue 1, 1997, Pages 149-155

  Byrne, Guerard W ^a   Mccurry, Kenneth R ^b,c   Martin, Michael J ^a   Mcclellan, S M ^a   Platt, Jeffrey L ^b   Logan, John S ^a  

^a Nextran   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; COMPLEMENT; DECAY ACCELERATING FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; BABOON; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; ENDOTHELIUM CELL; HEART TRANSPLANTATION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; SPECIES DIFFERENCE; SWINE; TRANSGENIC ANIMAL; XENOTRANSPLANTATION;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIGENS, CD55; ANTIGENS, CD59; CELLS, CULTURED; COMPLEMENT SYSTEM PROTEINS; GRAFT REJECTION; HUMANS; PAPIO; SPECIES SPECIFICITY; SWINE; TRANSGENES; TRANSPLANTATION, HETEROLOGOUS;

EID: 0031014159     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199701150-00027     Document Type: Article

References (34)

1. Platt JL, Fischel RJ, Matas AJ, Reif SA, Bolman RM, Bach FH. Immunopathology of hyperacute xenograft rejection in a swine-to-primate model. Transplantation 1991; 52: 214.
2. Platt JL, Vercellotti GM, Lindman BJ, Oegema TR, Bach FH, Dalmasso AP. Release of heparan sulfate from endothelial cells: implications for pathogenesis of hyperacute rejection. J Exp Med 1990; 171: 1363.
3. Dalmasso AP, Vercellotti GM, Fischel RJ, Bolman RM, Bach FH, Platt JL. Mechanisms of complement activation in the hyperacute rejection of porcine organs transplanted into primate recipients. Am J Pathol 1992; 140: 1157.
4. Cooper DKC, Human PA, Lexer G, et al. Effects of cyclosporine and antibody absorption on pig cardiac xenograft survival in the baboon. J Heart Transplant 1988; 7: 238.
5. Leventhal JR, Dalmasso AP, Cromwell JW, et al. Prolongation of cardiac xenograft survival by depletion of complement. Transplantation 1993; 55: 857.
6. Leventhal JR, Sakiyalak P, Witson J, et al. The synergistic effect of combined antibody and complement depletion on discordant cardiac xenograft survival in nonhuman primates. Transplantation 1994; 57: 974.
7. Leventhal JR, John R, Fryer JP, et al. Removal of baboon and human antiporcine IgG and IgM natural antibodies by immunoadsorption. Transplantation 1995; 59: 294.
8. Dalmasso AP, Vercellotti GM, Platt JL, Bach FB. Inhibition of complement-mediated endothelial cell cytotoxicity by decay-accelerating factor. Transplantation 1991; 52: 530.
9. Ninomiya H, Sims PJ. The human complement regulatory protein CD59 binds to the a-chain of C8 and to the "b" domain of C9. J Biol Chem 1992; 267: 13675.
10. Rollins SA, Zhao J, Ninomiya H, Sims PJ. Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9. Immunology 1991; 146: 2345.
11. Hansch GM, Hammer CH, Vanguri P, Shin ML. Homologous species restriction in lysis of erythrocytes by terminal complement proteins. Proc Natl Acad Sci USA 1981; 78: 5118.
12. Houle JJ, Hoffman EM. Evidence for restriction of the ability of complement to lyse homologous erythrocytes. J Immunol 1984; 133: 1444.
13. Atkinson JP, Oglesby TJ, White D, Adams EA, Liszenwski MK. Separation of self from non-self in the complement system: a role for membrane cofactor protein and decay accelerating factor. Clin Exp Immunol 1991; 86 (suppl 1): 27.
14. Fodor WL, Williams BL, Matis LA, et al. Expression of a functional human complement inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ rejection. Proc Natl Acad Sci USA 1994; 91: 11153.
15. Somerville CA, Kyriazis AG, McKenzie A, Allison J, Pearse MJ, D'Apice AJ. Functional expression of human CD59 in transgenic mice. Transplantation 1994; 58: 1430.
16. McCurry KR, Kooyman DL, Diamond LE, Byrne GW, Logan JS, Platt JL. Transgenic expression of human complement regulatory proteins in mice results in diminished complement deposition during organ xenoperfusion. Transplantation 1995; 59: 1177.
17. Byrne GW, McCurry KR, Kagan D, et al. Protection of xenogeneic cardiac endothelium from human complement by expression of CD59 or DAF in transgenic mice. Transplantation 1995; 60: 1149.
18. Diamond LE, McCurry KR, Oldham ER, et al. Human CD59 expressed in transgenic mouse hearts inhibits the activation of complement. Transplant Immunol 1995; 3: 305.
19. Kooyman DI, Byrne GW, McClellan S, et al. In vivo transfer of GPI-linked complement restriction factors from erythrocytes to the endothelium. Science 1995; 269: 89.
20. Rosengard Am, Cary NRB, Langford GA, Tucker AW, Wallwork J, White DJG. Tissue expression of human complement inhibitor, decay-accelerating factor, in transgenic pigs. Transplantation 1995; 59: 1325.
21. McCurry KR, Kooyman DL, Alvarado CG, et al. Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nature Med 1995; 1: 423.
22. Diamond LE, McCurry KR, Martin MJ, et al. Characterization of transgenic pigs expressing functionally active human CD59 on cardiac endothelium. Transplantation 1996; 61: 1241.
23. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156.
24. Church GM, Gilbert W. Genomic sequencing. Proc Natl Acad Sci USA 1984; 81: 1991.
25. Jaffe EA, Nachman RL, Becker GC, Minick CR. Culture of human endothelial cells derived from umbilical veins. J Clin Invest 1973; 52: 2744.
26. Voyta JC, Via DP, Butterfield CE, Zetter BR. Identification and isolation of endothelial cells based on their increased uptake of acetylated low density lipoprotein. J Cell Biol 1984; 99: 2034.
27. Meri S, Morgan BP, Davies A, et al. Human protectin (CD59), an 18,000-20,000 MW complement lysis restriction factor, inhibits C5b-8 catalyzed insertion of C9 into lipid bilayers. Immunology 1990; 71: 1.
28. Falk RJ, Dalmasso AP, Kim Y, et al. Neoantigen of the polymerized ninth component of complement: characterization of a monoclonal antibody and immunohistochemical localization in renal disease. J Clin Invest 1983; 72: 560.
29. Michler RE, McManus RP, Smith CR, Sadeghi AN, Rose EA. Technique for primate heterotopic cardiac xenotransplantation. J Med Primatol 1985; 14: 357.
30. Kaplon RJ, Michler RE, Xu H, Kwiatkowski PA, Edwards NM, Platt JL. Absence of hyperacute rejection in newborn pig-to-baboon cardiac xenografts. Transplantation 1994; 59: 1.
31. Medof ME, Kinoshita T, Nussenzweig V. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med 1984; 160: 1558.
32. Cozzi E, White DJG. The generation of transgenic pigs as potential organ donors for humans. Nature Med 1995; 1: 964.
33. Thompson C. Humanized pigs heart boost xenotransplantation. Lancet 1995; 346: 766.
34. Oldham ER, Velardo MA, Platt JL, Logan JS, Diamond L. High level tissue specific expression of human CD59, MCP and DAF proteins from genomic clones in transgenic mice. Transplant Proc 1996; 28: 693.